Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs

Provided By Globe Newswire

Last update: Mar 15, 2023

FORT COLLINS, Colo., March 15, 2023 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (OTCPK:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, is pleased to announce it has entered into a non-binding letter of intent (the "LOI") with Worksite Labs, Inc. ("WSL"), setting out the initial proposed terms and conditions pursuant to which the Company and Worksite Labs intend to affect a business combination by a merger structure to be determined involving the Company, one or more merger entities of the Company and WSL (the "Proposed Transaction").